Juan Carlos Hernández Boluda-rekin lankidetzan egindako argitalpenak (6)

2023

  1. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

2022

  1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

2021

  1. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

    Leukemia and Lymphoma

  2. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis

    Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2160-2172

2017

  1. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia

    British Journal of Haematology, Vol. 178, Núm. 5, pp. 764-771

2016

  1. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

    European Journal of Haematology, Vol. 96, Núm. 3, pp. 285-290